Cargando…

A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design to analysis of a clinical trial to address selection and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghadessi, Mercedeh, Tang, Rui, Zhou, Joey, Liu, Rong, Wang, Chenkun, Toyoizumi, Kiichiro, Mei, Chaoqun, Zhang, Lixia, Deng, C. Q., Beckman, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069184/
https://www.ncbi.nlm.nih.gov/pubmed/32164754
http://dx.doi.org/10.1186/s13023-020-1332-x
_version_ 1783505731268378624
author Ghadessi, Mercedeh
Tang, Rui
Zhou, Joey
Liu, Rong
Wang, Chenkun
Toyoizumi, Kiichiro
Mei, Chaoqun
Zhang, Lixia
Deng, C. Q.
Beckman, Robert A.
author_facet Ghadessi, Mercedeh
Tang, Rui
Zhou, Joey
Liu, Rong
Wang, Chenkun
Toyoizumi, Kiichiro
Mei, Chaoqun
Zhang, Lixia
Deng, C. Q.
Beckman, Robert A.
author_sort Ghadessi, Mercedeh
collection PubMed
description Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design to analysis of a clinical trial to address selection and inclusion of HCs, while maintaining scientific validity. This paper provides a comprehensive roadmap for planning, conducting, analyzing and reporting of studies using HCs, mainly when a randomized clinical trial is not possible. We review recent applications of HC in clinical trials, in which either predominantly a large treatment effect overcame concerns about bias, or the trial targeted a life-threatening disease with no treatment options. In contrast, we address how the evidentiary standard of a trial can be strengthened with optimized study designs and analysis strategies, emphasizing rare and pediatric indications. We highlight the importance of simulation and sensitivity analyses for estimating the range of uncertainties in the estimation of treatment effect when traditional randomization is not possible. Overall, the paper provides a roadmap for using HCs.
format Online
Article
Text
id pubmed-7069184
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70691842020-03-18 A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG) Ghadessi, Mercedeh Tang, Rui Zhou, Joey Liu, Rong Wang, Chenkun Toyoizumi, Kiichiro Mei, Chaoqun Zhang, Lixia Deng, C. Q. Beckman, Robert A. Orphanet J Rare Dis Review Historical controls (HCs) can be used for model parameter estimation at the study design phase, adaptation within a study, or supplementation or replacement of a control arm. Currently on the latter, there is no practical roadmap from design to analysis of a clinical trial to address selection and inclusion of HCs, while maintaining scientific validity. This paper provides a comprehensive roadmap for planning, conducting, analyzing and reporting of studies using HCs, mainly when a randomized clinical trial is not possible. We review recent applications of HC in clinical trials, in which either predominantly a large treatment effect overcame concerns about bias, or the trial targeted a life-threatening disease with no treatment options. In contrast, we address how the evidentiary standard of a trial can be strengthened with optimized study designs and analysis strategies, emphasizing rare and pediatric indications. We highlight the importance of simulation and sensitivity analyses for estimating the range of uncertainties in the estimation of treatment effect when traditional randomization is not possible. Overall, the paper provides a roadmap for using HCs. BioMed Central 2020-03-12 /pmc/articles/PMC7069184/ /pubmed/32164754 http://dx.doi.org/10.1186/s13023-020-1332-x Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Ghadessi, Mercedeh
Tang, Rui
Zhou, Joey
Liu, Rong
Wang, Chenkun
Toyoizumi, Kiichiro
Mei, Chaoqun
Zhang, Lixia
Deng, C. Q.
Beckman, Robert A.
A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
title A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
title_full A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
title_fullStr A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
title_full_unstemmed A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
title_short A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
title_sort roadmap to using historical controls in clinical trials – by drug information association adaptive design scientific working group (dia-adswg)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069184/
https://www.ncbi.nlm.nih.gov/pubmed/32164754
http://dx.doi.org/10.1186/s13023-020-1332-x
work_keys_str_mv AT ghadessimercedeh aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT tangrui aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT zhoujoey aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT liurong aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT wangchenkun aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT toyoizumikiichiro aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT meichaoqun aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT zhanglixia aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT dengcq aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT beckmanroberta aroadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT ghadessimercedeh roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT tangrui roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT zhoujoey roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT liurong roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT wangchenkun roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT toyoizumikiichiro roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT meichaoqun roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT zhanglixia roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT dengcq roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg
AT beckmanroberta roadmaptousinghistoricalcontrolsinclinicaltrialsbydruginformationassociationadaptivedesignscientificworkinggroupdiaadswg